PMC3420670_01
MRI T1-weighted scans on admission: (a) sagittal section, (b) coronal section.
CRIM.ENDOCRINOLOGY2011-941738.001.jpg
PMC3420670_01_CRIM.ENDOCRINOLOGY2011-941738.001.jpg
fig1
No other brain lesions were seen (Figures 1(a)-1(b)).
(a) Tissue of pituitary gland with cell-rich infiltrate of lymphoma. Large cells with nuclei display prominent nucleoli (magnification 40x). On red square adjacent area of lymphocytic hypophysitis. (b) Tumor cells express the B-cell marker CD20 and show dark membrane staining (magnification 40x).
CRIM.ENDOCRINOLOGY2011-941738.002.jpg
PMC3420670_01_CRIM.ENDOCRINOLOGY2011-941738.002.jpg
fig2
A group of cells suggestive of lymphocytic hypophysitis were also identified adjacent to the tumor (Figure 2(a)). Moreover, the tumor showed positive immunostain for B-cell markers CD20 and CD79 alpha (Figure 2(b)).
Histopathological finding of the adenomatous area with its typical monotonous cells (magnification 20x).
CRIM.ENDOCRINOLOGY2011-941738.003.jpg
PMC3420670_01_CRIM.ENDOCRINOLOGY2011-941738.003.jpg
fig3
In addition, a nonfunctional adenomatous area with its typical features was recognized close to the lymphoma (Figure 3).
(a) Negative whole body PET/CT scan. (b) Bone marrow aspiration sample evidencing normal parenchyma.
CRIM.ENDOCRINOLOGY2011-941738.004.jpg
PMC3420670_01_CRIM.ENDOCRINOLOGY2011-941738.004.jpg
fig4
Since the lymphoma was very well localized (Stage I-E) and whole body 18F-FDG PET/CT and bone marrow biopsy excluded disseminated disease, no systemic chemotherapy was suggested (Figure 4).